Interview with Marcin Hanczaruk, General Manager, Ferring Pharmaceuticals Poland
As we are just entering 2011, could you share with us the results of the Polish affiliate in 2010? 2010 was for Ferring Poland a year of reconstruction. The affiliate…
Address: ul. Bonifraterska 17
00-203 Warszawa
Poland
Tel: +48 22 246 0680
Ferring Pharmaceuticals is a research-driven biopharmaceutical company devoted to identifying, developing and marketing innovative products in the fields of reproductive health, urology, gastroenterology, endocrinology and osteoarthritis.
The company’s research activities and products are connected by a common thread focused on the provision of tailored treatments that work on the body’s own terms to enable doctors to combat numerous diseases and medical conditions.
The company has gained international recognition over the last 20 years for the creation of inventive medications that improve the quality of life of children and adults all around the world.
Ferring has its own production facilities in several European countries, in South America, Israel and China. With the acquisition of Bio-Technology General in 2005, it has capabilities in recombinant biotechnology as well as more traditional pharmaceutical manufacturing.
Ferring’s marketing, medical services and sales teams, led by corporate headquarters in Saint-Prex, Switzerland, operate from more than 45 countries and employ more than 3700 people throughout the world, while treatments are available in more than 70 countries. This expansion has allowed Ferring to maintain a double digit annual growth rate over the last two decades.
Ferring’s R&D projects complement Ferring’s product portfolio and will add a new generation of products to some of the company’s most successful specialty brands. R&D facilities are located in Denmark, Israel and California, USA.
Ferring is committed to a future where it will continue to provide new and innovative medicines by utilising existing and acquired skills and the development of pioneering technologies and, where necessary, through partnerships with academic institutes and other companies.
For fifty years, we have been at the forefront of innovation in the field of naturally occurring human peptides. We have developed treatments in areas that span the human life cycle, including: reproductive health, endocrinology, gastroenterology and urology:
Ferring’s infertility treatments give infertile couples the chance to have babies
In obstetrics, Ferring helps premature children to be born healthy and without handicaps
With treatments in endocrinology, Ferring gives children the chance to overcome growth deficiencies
Ferring’s inflammatory bowel disease (IBD) treatments enable young adults with IBD to live a normal life
In urology, Ferring’s treatment for nocturia and bedwetting helps adults and children to an undisturbed night’s sleep
Ferring’s testosterone replacement treatment improves the key symptoms of low testosterone, reduces fat and improves muscle strength and mood
Ferring’s hormonal therapy for prostate cancer offers a new treatment option to men with an advanced hormone-dependent cancer
Ferring’s strength is our extensive knowledge of peptides and the role they play in the human body.
As we are just entering 2011, could you share with us the results of the Polish affiliate in 2010? 2010 was for Ferring Poland a year of reconstruction. The affiliate…
Zszisław Sabiłło, president of the Polish Association of the Pharmaceutical Industry Employers (PZPPF), discusses the significance of the Polish generics market in terms of volume and sales market share, and…
Poland’s entrance into the EU has been a catalyst for growth that has allowed the country to flourish, shown by the nation’s ranking as the eighth largest economy in Europe according…
“Cost containment measures are not just a Polish story, but a European reality,” says Marcin Hanczaruk, general manager at Amgen. “The Reimbursement Act is a real revolution, but it has…
The general director of Actavis Poland talks about competing in an intense generics market, and the company’s potential in Poland given the country’s 2012 Reimbursement Act. The year 2012 was…
AstraZeneca’s General Manager in Poland discuses AstraZeneca’s strategic realignment to become a highly specialized biotech company after 20 years of presence in Poland. He stresses the importance of the affiliate’s…
Novascon Pharmaceuticals is the second fastest growing company in the OTC/dietary supplement market in Poland. Its founder shares the reasons behind this success, including his strategy to sell their main…
Omega Pharma is a pharmacist champion and one of the fastest growing OTC companies in Poland. Its General Manager in Poland discusses the shift taking place with Pharmacies now becoming…
Schulke Poland’s General Manager wants the affiliate: “to be recognized as a high quality “one stop shop” for hygiene and disinfection. He also comments: “Poland is quite advanced in terms…
The department of innovation and industry under the Ministry of Economy has been preparing a new project called: “Pharmaceutical Industry Mapping.” Its leader hopes: “that the outcome of this exercise…
Bristol-Myers Squibb’s General Manager in Poland stresses the urgent need to allow more innovative drugs to fight against deadly diseases, especially in the field of immune-oncology which he says will:…
Unipharm Poland’s country manager explains what is needed to become a successful OTC and dietary supplement company in Poland, saying that it is “key to master the marketing mix but…
Budget limitations in the Polish vaccine field are a handicap to improving patients’ lives as Sanofi Pasteur General Manager comments: “the National Health Fund’s budget for reimbursement is around EUR…
See our Cookie Privacy Policy Here